The Protein Expression Core will provide monoclonal antibodies (mAb) and recombinant chimeric Fc fusion proteins to support all programs of this NCDDG. The Core will provide purified and characterized proteins, suitable for both the in vitro and in vivo analyses. This centralized core will allow for comparative studies among this NCDDG since these agents will be used from equivalent, quality control lots of production. The in vivo feasibility and optimization data generated using the Core-generated reagents will be suitable for including in investigator-initiated INDs submitted to support the clinical trials that arise from this NCDDG program. Each agent will be expressed, purified, and subjected to quality control studies and each agent will be produced under standard operating procedures, tested, and distributed to investigators in the program as needed. Specifically, we are going to express and purify recombinant Fc-fusion proteins and mAbs, perform quality control assays to demonstrate and quantitate bioactivity, perform sterility and endotoxin testing, and and distribute to all investigators.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Keenan, Bridget P; Saenger, Yvonne; Kafrouni, Michel I et al. (2014) A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 146:1784-94.e6
Yao, Sheng; Zhu, Yuwen; Chen, Lieping (2013) Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 12:130-46
Zhu, Yuwen; Yao, Sheng; Iliopoulou, Bettina P et al. (2013) B7-H5 costimulates human T cells via CD28H. Nat Commun 4:2043
Yao, Sheng; Zhu, Yuwen; Zhu, Gefeng et al. (2011) B7-h2 is a costimulatory ligand for CD28 in human. Immunity 34:729-40
Uram, Jennifer N; Black, Chelsea M; Flynn, Emilee et al. (2011) Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. J Immunol 186:3847-57
Zhang, Yu-Qian; Tsai, Ya-Chea; Monie, Archana et al. (2010) Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther 18:692-9
Mao, Chih-Ping; Wu, T-C (2010) Inhibitory RNA molecules in immunotherapy for cancer. Methods Mol Biol 623:325-39
Kim, Daejin; Hoory, Talia; Monie, Archana et al. (2010) Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors. J Biomed Sci 17:61
Pfannenstiel, Lukas W; Lam, Samuel S K; Emens, Leisha A et al. (2010) Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol 263:79-87
Chang, Chih-Long; Ma, Barbara; Pang, Xiaowu et al. (2009) Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther 17:1365-72

Showing the most recent 10 out of 34 publications